chloroquine has been researched along with Pneumonia, Pneumocystis in 4 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Pneumonia, Pneumocystis: A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The widespread emergence of chloroquine-resistant Plasmodium falciparum led to the formulation of an effective, fixed combination of two antimalarial agents, pyrimethamine and the long-acting sulfonamide sulfadoxine, for prophylaxis and treatment." | 4.77 | Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. ( Hewlett, EL; Pearson, RD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomes, A | 1 |
| Ferraz, R | 1 |
| Ficker, L | 1 |
| Collins, MS | 1 |
| Prudêncio, C | 1 |
| Cushion, MT | 1 |
| Teixeira, C | 1 |
| Gomes, P | 1 |
| Laurens, MB | 1 |
| Mungwira, RG | 1 |
| Nyirenda, OM | 1 |
| Divala, TH | 1 |
| Kanjala, M | 1 |
| Muwalo, F | 1 |
| Mkandawire, FA | 1 |
| Tsirizani, L | 1 |
| Nyangulu, W | 1 |
| Mwinjiwa, E | 1 |
| Taylor, TE | 1 |
| Mallewa, J | 1 |
| Blackwelder, WC | 1 |
| Plowe, CV | 1 |
| Laufer, MK | 1 |
| van Oosterhout, JJ | 1 |
| von Sonnenburg, F | 1 |
| Prüfer, L | 1 |
| Pearson, RD | 1 |
| Hewlett, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open-label Controlled Trial of Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on Anti-retroviral Therapy in Malawi[NCT01650558] | 1,499 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099] | Phase 3 | 723 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 0 |
| Chloroquine (CQ) Prophylaxis | 0.24 |
| Discontinuation of Standard of Care (Control Arm) | 0 |
Incidence of bacterial infections and malaria (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 27.8 |
| Chloroquine (CQ) Prophylaxis | 37.4 |
| Discontinuation of Standard of Care (Control Arm) | 36.3 |
Number of Participants with at Least One CD4 Count <200 (NCT01650558)
Timeframe: Every 6 months for 22-66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 24 |
| Chloroquine (CQ) Prophylaxis | 23 |
| Discontinuation of Standard of Care (Control Arm) | 27 |
Number of participants who ever have a detectable viral load (>400 copies/ml). (NCT01650558)
Timeframe: Throughout study participation, measured every six months (2-5.5 years).
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 24 |
| Chloroquine (CQ) Prophylaxis | 36 |
| Discontinuation of Standard of Care (Control Arm) | 33 |
Incidence of severe events (composite of death and WHO stage 3 and 4 illness) (NCT01650558)
Timeframe: 22-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 3.3 |
| Chloroquine (CQ) Prophylaxis | 4.2 |
| Discontinuation of Standard of Care (Control Arm) | 4.2 |
Incidence of any WHO HIV stage 2, 3, or 4 illness (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 4.0 |
| Chloroquine (CQ) Prophylaxis | 5.7 |
| Discontinuation of Standard of Care (Control Arm) | 5.8 |
2 reviews available for chloroquine and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
[Progress in immunodiagnosis and chemotherapy of protozoan infections].
Topics: Amebiasis; Animals; Antibodies; Babesiosis; Chloroquine; Drug Resistance, Microbial; Giardiasis; Hum | 1983 |
Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii.
Topics: Acquired Immunodeficiency Syndrome; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria | 1987 |
1 trial available for chloroquine and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Retroviral Agents; Antimalarials; | 2016 |
1 other study available for chloroquine and Pneumonia, Pneumocystis
| Article | Year |
|---|---|
Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens.
Topics: A549 Cells; Antimalarials; Cell Line, Tumor; Chloroquine; Humans; Immunocompromised Host; Pneumocyst | 2018 |